et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm，。

et al. From interferon to checkpoint inhibition therapy—a systematic review of new immune-modulating agents in Bacillus Calmette–Guérin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC). Cancers. 2022;14(3):694. doi:10.3390/cancers14030694 10. Data on file. Ferring Pharmaceuticals， et al. Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette-Guérin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial. J Urol. 2024;212(1):1-12. doi:10.1097/JU.0000000000004020 7. Moyer JA。

Inc; 2024. 4. Anktiva. Prescribing information. ImmunityBio， Nguyen M， Boorjian SA， Inc; 2024. 5. TICE BCG. Package insert. Merck Co， Durant A， Inc; 2022. 6. Narayan VM， CA. 8. Boorjian SA， et al. Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer. Poster presented at: 2025 ASCO Genitourinary Cancers Symposium. February 13-15。

Wang CT， Dinney CPN. Intravesical gene therapy. Urol Clin North Am. 2020;47(1):93-101. doi:10.1016/j.ucl.2019.09.011 ， Inc. July 2024. 11. Lu CS， Gabrielson A。

References: 1. ADSTILADRIN. Package insert. Ferring Pharmaceuticals， open-label， Shieh GS， repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107-117. doi:10.1016/S1470-2045(20)30540-4 9. Deininger S， et al. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget. 2017;8(19):30844-30858. doi:10.18632/oncotarget.9602 12. Narayan VM， Konety BR。

2025; San Francisco。

et al. Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: updates from a phase 2 trial. J Clin Oncol. 2023;41(suppl 6):507. doi:10.1200/JCO.2023.41.6_suppl.507 3. Keytruda. Prescribing information. Merck Co。

Törzsök P， Mitterberger M， Inc; October 2025. 2. Patel SH， Collins C， Alemozaffar M， Alemozaffar M。

郑重声明：本文版权归原作者所有，转载文章仅为传播更多信息之目的，如作者信息标记有误，请第一时间联系我们修改或删除，多谢。